جميع الدراسات
التوظيفالمرحلة 3تدخلي

A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping

This study is a Phase 3 clinical trial testing a new medicine called AOC 1044, also known as delpacibart zotadirsen, for boys with Duchenne Muscular Dystrophy (DMD). It's specifically for those whose DMD is caused by a genetic change that could be helped by 'exon 44 skipping'. Researchers want to find out if this new medicine is safe and effective in slowing down the progression of DMD. Participants will receive either the real medicine or a placebo (a dummy medicine) through a drip. The study is designed to be very careful, checking health and progress over about two years, and then continuing with everyone receiving the active medicine.

نظرة سريعة

الحالة
التوظيف
المرحلة
المرحلة 3
الراعي
شركة أفيدتي للعلوم البيولوجية.
الهدف من التسجيل
70
ابدأ
01 سبتمبر 2026
التاريخ المتوقع للانتهاء
01 Jul 2030

ما هو موضوع هذه الدراسة؟

This study is a major research project, known as a Phase 3 trial, designed to test a new medicine called AOC 1044 (you might also hear it called delpacibart zotadirsen). It's specifically for boys living with Duchenne Muscular Dystrophy (DMD). DMD is a serious muscle-wasting condition that gets worse over time. The goal of this research is to see if this new medicine can safely help with the condition and slow down its effects by targeting a specific genetic problem in some boys with DMD.

For most people with DMD, the body can't make a very important protein called dystrophin, which muscles need to work properly. This study focuses on boys whose DMD is caused by a genetic mistake that affects 'exon 44' of the dystrophin gene. The medicine, AOC 1044, is designed to 'skip' over this faulty part of the gene, allowing the body to produce a shorter, but still working, version of the dystrophin protein. This could potentially help muscles work better and be stronger.

Finding new treatments for DMD is very important to improve the quality of life for those affected. This study aims to gather strong evidence about whether AOC 1044 is a safe and effective option that could one day be available more widely.

النقاط الرئيسية

  • This is a Phase 3 study for Duchenne Muscular Dystrophy (DMD) in boys aged 7-16.
  • It tests a new medicine (AOC 1044) for a specific genetic type of DMD (exon 44 skipping).
  • Participants will receive the medicine or a placebo by drip every 6 weeks.
  • The study lasts over two years, with everyone getting the active medicine in the second year.
  • It aims to see if the medicine is safe and can help improve muscle function.
  • Strict eligibility rules apply, including your age and specific genetic test results.

من قد يكون مؤهلاً؟

This study is looking for boys with Duchenne Muscular Dystrophy (DMD) who meet certain requirements. They must be able to walk and have a clear diagnosis of DMD confirmed by genetic tests. Importantly, their genetic test results must show a specific type of mutation that the medicine is designed to target, known as 'exon 44 skipping'. Boys must be between 7 and 16 years old when they agree to take part, and they need to have been on a stable dose of steroid medication (including Vamorolone) for at least six months before starting the study.

There are also some reasons why someone might not be able to join. This includes boys who have previously had gene therapy or certain cell treatments. If they've had other similar types of medicine called 'oligonucleotides' in the last six months (not including COVID-19 vaccines), they also won't be able to join. Certain recent changes to other medications like growth hormone, testosterone, or givinostat might also prevent participation, as these need to be stable for a set period before the study starts. Regular blood tests and assessments will be done to ensure everyone is suitable and safe to participate.

هل يمكن أن تناسبك هذه الدراسة؟

أجب عن هذه الأسئلة السريعة لترى ما إذا كنت مؤهلاً. هذا دليل فقط - الفريق البحثي هو الذي يتخذ القرار النهائي.

  1. Are you a boy with a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD)?
  2. Does your genetic test show the 'exon 44 skipping' type of mutation?
  3. Are you currently able to walk?
  4. Are you between 7 and 16 years old?
  5. Have you been on a stable dose of steroid medication for at least 6 months?
  6. Have you *not* had gene therapy or certain cell treatments before?
أجب عن كل سؤال لترى نتيجتك.

ماذا يتضمن المشاركة؟

If you decide to take part, you'll first have a 'screening period' of up to 44 days to check if you're suitable. After that, you'll be randomly assigned to one of two groups for about a year (54 weeks). One group will receive the new medicine, AOC 1044, and the other will receive a placebo (a dummy medicine that looks the same but contains no active drug). Neither you, your family, nor the study doctors will know which you are receiving during this time.

The medicine (or placebo) will be given through a drip into your arm at the study clinic once every six weeks, for a total of nine doses. Throughout this period, you'll have regular visits for check-ups, assessments of your muscle strength and movement, and safety tests like blood samples. After this first year, everyone who wants to can enter an 'open-label' period. This means everyone will then receive the actual AOC 1044 medicine for another year (54 weeks), again given every six weeks for nine more doses. The final dose will be at around week 102, followed by a final health check-up a few weeks later, and then a safety follow-up visit. The total study duration, including follow-up, will be around two years and two months.

المخاطر والفوائد المحتملة

Taking part in a clinical trial offers the chance to potentially benefit from a new treatment before it's widely available, and you'd be contributing valuable information that could help others with DMD in the future. However, there's no guarantee the medicine will help you, and you might receive the placebo instead of the active drug during the first part of the study. All medicines have potential side effects, and while the study will closely monitor your health, there might be risks that are not yet fully known. You would always be fully informed of any known risks. Importantly, you have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

المواقع (20)

  • The Children's Hospital at Westmead
    الرمز البريدي المؤكد
    ويستميد، أستراليا· التوظيف
  • مستشفى جامعة لوفين
    الرمز البريدي المؤكد
    لوفين، بلجيكا· التوظيف
  • Centre Hospitalier Régional de la Citadelle
    الرمز البريدي المؤكد
    لييج، بلجيكا· التوظيف
  • London Health Sciences Centre - Victoria Hospital
    الرمز البريدي المؤكد
    لندن، كندا· التوظيف
  • CHU de Nantes - Hotel-Dieu
    الرمز البريدي المؤكد
    نانت، فرنسا· التوظيف
  • AP-HP Hospital Armand-Trousseau
    الرمز البريدي المؤكد
    باريس، فرنسا· التوظيف
  • مستشفى جامعة إيسن
    الرمز البريدي المؤكد
    إيسن، ألمانيا· التوظيف
  • Universitaetsklinikum Heidelberg
    الرمز البريدي المؤكد
    هايدلبرغ، ألمانيا· التوظيف
  • Klinikum der Ludwig-Maximilians-Universitaet Muenchen
    الرمز البريدي المؤكد
    ميونخ، ألمانيا· التوظيف
  • Istituto Giannina Gaslini
    الرمز البريدي المؤكد
    جنوة، إيطاليا· التوظيف
  • Fondazione Serena ETS - Centro Clinico NeMO Milano
    الرمز البريدي المؤكد
    ميلانو، إيطاليا· التوظيف
  • IRCCS Ospedale San Raffaele
    الرمز البريدي المؤكد
    ميلانو، إيطاليا· التوظيف

أسئلة شائعة

What is 'exon 44 skipping'?

It's a way the medicine tries to fix a specific genetic mistake in your DNA that causes DMD, by 'skipping over' the faulty part to help your body make a working muscle protein.

ما هو "العلاج الوهمي"؟

A placebo is a dummy medicine that looks exactly like the real medicine but contains no active drug. It helps researchers compare how well the real medicine works.

هل سأعرف إذا كنت أحصل على الدواء الحقيقي أم الدواء الوهمي؟

During the first year, neither you nor your study doctor will know. This is to make sure results are fair. After that, everyone gets the real medicine if they choose to continue.

كيف يتم إعطاء الدواء؟

The medicine is given through a drip into a vein, usually in your arm, at the study clinic once every six weeks.

كم من الوقت سأكون في الدراسة؟

The study lasts for about two years and two months in total, including regular treatments, check-ups, and a final safety follow-up.

كيفية معرفة المزيد

Avidity Bioscience, Inc., A Novartis Company

تحدث دائمًا إلى طبيبك العام أو الأخصائي قبل اتخاذ قرار بالمشاركة في دراسة.

هل أنت مهتم بالمشاركة؟

سجل اهتمامك

شارك تفاصيلك وفريق البحث لـ "A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1… "سيتواصل معك إذا كنت مؤهلاً. تحدث دائمًا إلى طبيبك قبل الموافقة على المشاركة.

نقاش

مناقشة المجتمع

مدعوم من منتدانا في community.patient.info. يرجى التحلي بالاحترام — هذه ليست نصيحة طبية.